Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model

Neuron

Volumn 92, Issue 2, 2016, Pages 407-418

  Lasagna Reeves, Cristian A ^a,b   de Haro, Maria ^a,b   Hao, Shuang ^a,b   Park, Jeehye ^a,b,d   Rousseaux, Maxime W C ^a,b   Al Ramahi, Ismael ^a,b   Jafar Nejad, Paymaan ^a,b,e   Vilanova Velez, Luis ^a,b   See, Lauren ^a,b   De Maio, Antonia ^a,b   Nitschke, Larissa ^a,b   Wu, Zhenyu ^a,b   Troncoso, Juan C ^c   Westbrook, Thomas F ^b   Tang, Jianrong ^a,b   Botas, Juan ^a,b   Zoghbi, Huda Y ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e ISIS PHARMACEUTICALS   (United States)

Author keywords

neurodegeneration; Nuak1; tau levels; tau phosphorylation

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN NUAK1; SERINE; TAU PROTEIN; UNCLASSIFIED DRUG; NUAK1 PROTEIN, HUMAN; NUAK1 PROTEIN, MOUSE; PROTEIN KINASE; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; BRAIN TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; DROSOPHILA; GENETIC SCREENING; HAPLOINSUFFICIENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; MOUSE MODEL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN PHOSPHORYLATION; STEADY STATE; TAUOPATHY; ALZHEIMER DISEASE; ANIMAL; ANIMAL BEHAVIOR; CONDITIONING; DISEASE MODEL; FEAR; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOBLOTTING; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ALZHEIMER DISEASE; ANIMALS; BEHAVIOR, ANIMAL; CELL LINE, TUMOR; CONDITIONING (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DROSOPHILA; FEAR; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; MICE; PHOSPHORYLATION; PROTEIN KINASES; REPRESSOR PROTEINS; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS; TAUOPATHIES;

EID: 84992025495     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2016.09.022     Document Type: Article

References (51)

1. Ando, K., Maruko-Otake, A., Ohtake, Y., Hayashishita, M., Sekiya, M., Iijima, K.M., Stabilization of microtubule-unbound tau via tau phosphorylation at Ser262/356 by Par-1/MARK contributes to augmentation of AD-related phosphorylation and Aβ42-induced tau toxicity. PLoS Genet., 12, 2016, e1005917.
2. Banerjee, S., Buhrlage, S.J., Huang, H.T., Deng, X., Zhou, W., Wang, J., Traynor, R., Prescott, A.R., Alessi, D.R., Gray, N.S., Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases. Biochem. J. 457 (2014), 215–225.
3. Biernat, J., Mandelkow, E.M., The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains. Mol. Biol. Cell 10 (1999), 727–740.
4. Biernat, J., Wu, Y.Z., Timm, T., Zheng-Fischhöfer, Q., Mandelkow, E., Meijer, L., Mandelkow, E.M., Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol. Biol. Cell 13 (2002), 4013–4028.
5. Buée, L., Bussière, T., Buée-Scherrer, V., Delacourte, A., Hof, P.R., Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33 (2000), 95–130.
6. Cavallini, A., Brewerton, S., Bell, A., Sargent, S., Glover, S., Hardy, C., Moore, R., Calley, J., Ramachandran, D., Poidinger, M., et al. An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease. J. Biol. Chem. 288 (2013), 23331–23347.
7. Chiti, F., Dobson, C.M., Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75 (2006), 333–366.
8. Clark, L.N., Poorkaj, P., Wszolek, Z., Geschwind, D.H., Nasreddine, Z.S., Miller, B., Li, D., Payami, H., Awert, F., Markopoulou, K., et al. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc. Natl. Acad. Sci. USA 95 (1998), 13103–13107.
9. Davis, S., Bliss, T.V., Dutrieux, G., Laroche, S., Errington, M.L., Induction and duration of long-term potentiation in the hippocampus of the freely moving mouse. J. Neurosci. Methods 75 (1997), 75–80.
10. Dickey, C.A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R.M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C.B., et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 117 (2007), 648–658.
11. Dickey, C.A., Koren, J., Zhang, Y.J., Xu, Y.F., Jinwal, U.K., Birnbaum, M.J., Monks, B., Sun, M., Cheng, J.Q., Patterson, C., et al. Akt and CHIP coregulate tau degradation through coordinated interactions. Proc. Natl. Acad. Sci. USA 105 (2008), 3622–3627.
12. Hao, S., Tang, B., Wu, Z., Ure, K., Sun, Y., Tao, H., Gao, Y., Patel, A.J., Curry, D.J., Samaco, R.C., et al. Forniceal deep brain stimulation rescues hippocampal memory in Rett syndrome mice. Nature 526 (2015), 430–434.
13. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
14. Harper, S.Q., Staber, P.D., He, X., Eliason, S.L., Martins, I.H., Mao, Q., Yang, L., Kotin, R.M., Paulson, H.L., Davidson, B.L., RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA 102 (2005), 5820–5825.
15. Hutton, M., Lendon, C.L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393 (1998), 702–705.
16. Jones, M.W., Errington, M.L., French, P.J., Fine, A., Bliss, T.V., Garel, S., Charnay, P., Bozon, B., Laroche, S., Davis, S., A requirement for the immediate early gene Zif268 in the expression of late LTP and long-term memories. Nat. Neurosci. 4 (2001), 289–296.
17. Ma, Q.L., Yang, F., Rosario, E.R., Ubeda, O.J., Beech, W., Gant, D.J., Chen, P.P., Hudspeth, B., Chen, C., Zhao, Y., et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 29 (2009), 9078–9089.
18. Mairet-Coello, G., Courchet, J., Pieraut, S., Courchet, V., Maximov, A., Polleux, F., The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation. Neuron 78 (2013), 94–108.
19. Malenka, R.C., Bear, M.F., LTP and LTD: an embarrassment of riches. Neuron 44 (2004), 5–21.
20. Malleret, G., Haditsch, U., Genoux, D., Jones, M.W., Bliss, T.V., Vanhoose, A.M., Weitlauf, C., Kandel, E.R., Winder, D.G., Mansuy, I.M., Inducible and reversible enhancement of learning, memory, and long-term potentiation by genetic inhibition of calcineurin. Cell 104 (2001), 675–686.
21. Miller, T.M., Kaspar, B.K., Kops, G.J., Yamanaka, K., Christian, L.J., Gage, F.H., Cleveland, D.W., Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann. Neurol. 57 (2005), 773–776.
22. Morris, M., Maeda, S., Vossel, K., Mucke, L., The many faces of tau. Neuron 70 (2011), 410–426.
23. Nishimura, I., Yang, Y., Lu, B., PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116 (2004), 671–682.
24. Noble, M.E., Endicott, J.A., Johnson, L.N., Protein kinase inhibitors: insights into drug design from structure. Science 303 (2004), 1800–1805.
25. Otvos, L. Jr., Feiner, L., Lang, E., Szendrei, G.I., Goedert, M., Lee, V.M., Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res. 39 (1994), 669–673.
26. Park, J., Al-Ramahi, I., Tan, Q., Mollema, N., Diaz-Garcia, J.R., Gallego-Flores, T., Lu, H.C., Lagalwar, S., Duvick, L., Kang, H., et al. RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature 498 (2013), 325–331.
27. Paxinos, G., Franklin, K.B.J., The Mouse Brain in Stereotaxic Coordinates. 2001, Academic Press.
28. Petrucelli, L., Dickson, D., Kehoe, K., Taylor, J., Snyder, H., Grover, A., De Lucia, M., McGowan, E., Lewis, J., Prihar, G., et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13 (2004), 703–714.
29. Pickhardt, M., von Bergen, M., Gazova, Z., Hascher, A., Biernat, J., Mandelkow, E.M., Mandelkow, E., Screening for inhibitors of tau polymerization. Curr. Alzheimer Res. 2 (2005), 219–226.
30. Pittman, A.M., Fung, H.C., de Silva, R., Untangling the tau gene association with neurodegenerative disorders. Hum. Mol. Genet. 15 (2006), R188–R195.
31. Roberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F., Cheng, I.H., Wu, T., Gerstein, H., Yu, G.Q., Mucke, L., Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316 (2007), 750–754.
32. Rovelet-Lecrux, A., Campion, D., Copy number variations involving the microtubule-associated protein tau in human diseases. Biochem. Soc. Trans. 40 (2012), 672–676.
33. Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (2005), 476–481.
34. Small, S.A., Duff, K., Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60 (2008), 534–542.
35. Sun, X., Gao, L., Chien, H.Y., Li, W.C., Zhao, J., The regulation and function of the NUAK family. J. Mol. Endocrinol. 51 (2013), R15–R22.
36. Suzuki, A., Kusakai, G., Kishimoto, A., Shimojo, Y., Miyamoto, S., Ogura, T., Ochiai, A., Esumi, H., Regulation of caspase-6 and FLIP by the AMPK family member ARK5. Oncogene 23 (2004), 7067–7075.
37. Suzuki, A., Ogura, T., Esumi, H., NDR2 acts as the upstream kinase of ARK5 during insulin-like growth factor-1 signaling. J. Biol. Chem. 281 (2006), 13915–13921.
38. Takashima, A., Honda, T., Yasutake, K., Michel, G., Murayama, O., Murayama, M., Ishiguro, K., Yamaguchi, H., Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci. Res. 31 (1998), 317–323.
39. Takeuchi, H., Iba, M., Inoue, H., Higuchi, M., Takao, K., Tsukita, K., Karatsu, Y., Iwamoto, Y., Miyakawa, T., Suhara, T., et al. P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS ONE, 6, 2011, e21050.
40. Tang, J., Dani, J.A., Dopamine enables in vivo synaptic plasticity associated with the addictive drug nicotine. Neuron 63 (2009), 673–682.
41. Vingtdeux, V., Davies, P., Dickson, D.W., Marambaud, P., AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol. 121 (2011), 337–349.
42. Wang, Y., Mandelkow, E., Tau in physiology and pathology. Nat. Rev. Neurosci. 17 (2016), 5–21.
43. Westbrook, T.F., Hu, G., Ang, X.L., Mulligan, P., Pavlova, N.N., Liang, A., Leng, Y., Maehr, R., Shi, Y., Harper, J.W., Elledge, S.J., SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 452 (2008), 370–374.
44. Whitlock, J.R., Heynen, A.J., Shuler, M.G., Bear, M.F., Learning induces long-term potentiation in the hippocampus. Science 313 (2006), 1093–1097.
45. Williams, A.J., Paulson, H.L., Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci. 31 (2008), 521–528.
46. Xia, H., Mao, Q., Eliason, S.L., Harper, S.Q., Martins, I.H., Orr, H.T., Paulson, H.L., Yang, L., Kotin, R.M., Davidson, B.L., RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10 (2004), 816–820.
47. Yoshida, H., Goedert, M., Phosphorylation of microtubule-associated protein tau by AMPK-related kinases. J. Neurochem. 120 (2012), 165–176.
48. Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.M., Iwata, N., Saido, T.C., Maeda, J., Suhara, T., Trojanowski, J.Q., Lee, V.M., Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53 (2007), 337–351.
49. Zempel, H., Thies, E., Mandelkow, E., Mandelkow, E.M., Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 30 (2010), 11938–11950.
50. Zou, F., Chai, H.S., Younkin, C.S., Allen, M., Crook, J., Pankratz, V.S., Carrasquillo, M.M., Rowley, C.N., Nair, A.A., Middha, S., et al., Alzheimer's Disease Genetics Consortium. Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet., 8, 2012, e1002707.
51. Zu, T., Duvick, L.A., Kaytor, M.D., Berlinger, M.S., Zoghbi, H.Y., Clark, H.B., Orr, H.T., Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. 24 (2004), 8853–8861.